Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) has been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $49.1429.

A number of analysts recently weighed in on the stock. Stifel Nicolaus increased their price objective on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Bank of America raised their price target on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research note on Friday. Wall Street Zen raised Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Finally, HC Wainwright set a $56.00 price objective on Mineralys Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 10th.

More Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: NDA accepted by FDA and PDUFA set (Dec. 22, 2026) for lorundrostat — formal regulatory review underway, which de-risks timing for potential approval and commercialization. GlobeNewswire: Q4 results & NDA acceptance
• Positive Sentiment: Q4 results surprised to the upside — reported EPS of ($0.40) vs. consensus ($0.57), suggesting operational execution beat expectations and reducing near-term downside to estimates. MarketBeat: Q4 earnings summary
• Positive Sentiment: Management is actively preparing for launch and payer engagement ahead of the regulatory decision — signaling commercialization planning and market-access work that could speed uptake if approved. Seeking Alpha: Launch & payer engagement
• Neutral Sentiment: Conference call and transcript provide management’s roadmap and data context (Q4 call reviewed NDA strategy, clinical data and next steps); useful for modeling but not a surprise item. Seeking Alpha: Earnings call transcript
• Neutral Sentiment: Press coverage highlights steady progress with FDA interactions and public messaging; these articles reiterate facts rather than deliver new catalysts. Yahoo Finance: FDA progress TipRanks: NDA acceptance overview
• Negative Sentiment: Critical commentary warns of potential interference from larger pharma interests that could complicate the approval or market dynamics — introduces regulatory and competitive risk that can pressure shares. Seeking Alpha: Concerns over big pharma pressure

Insider Activity at Mineralys Therapeutics

In related news, insider David Malcom Rodman sold 2,171 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $26.84, for a total value of $58,269.64. Following the completion of the sale, the insider owned 82,489 shares of the company’s stock, valued at $2,214,004.76. This represents a 2.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jon Congleton sold 16,236 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $32.62, for a total transaction of $529,618.32. Following the completion of the sale, the chief executive officer directly owned 639,151 shares of the company’s stock, valued at approximately $20,849,105.62. This represents a 2.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 342,919 shares of company stock worth $11,755,439 over the last ninety days. 33.24% of the stock is currently owned by corporate insiders.

Institutional Trading of Mineralys Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. lifted its position in shares of Mineralys Therapeutics by 19.1% during the 3rd quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock valued at $277,717,000 after acquiring an additional 1,176,470 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Mineralys Therapeutics by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 3,352,880 shares of the company’s stock worth $121,676,000 after acquiring an additional 333,881 shares during the last quarter. State Street Corp grew its holdings in shares of Mineralys Therapeutics by 144.4% in the 4th quarter. State Street Corp now owns 3,184,999 shares of the company’s stock worth $115,584,000 after acquiring an additional 1,881,976 shares during the last quarter. Caligan Partners LP raised its position in shares of Mineralys Therapeutics by 37.4% during the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock worth $105,139,000 after purchasing an additional 755,302 shares during the period. Finally, Suvretta Capital Management LLC lifted its holdings in shares of Mineralys Therapeutics by 22.2% during the third quarter. Suvretta Capital Management LLC now owns 2,132,133 shares of the company’s stock valued at $80,850,000 after purchasing an additional 387,641 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors.

Mineralys Therapeutics Trading Down 3.0%

Shares of Mineralys Therapeutics stock opened at $26.19 on Monday. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -11.05 and a beta of 0.57. Mineralys Therapeutics has a twelve month low of $10.44 and a twelve month high of $47.65. The business’s 50 day simple moving average is $30.45 and its 200-day simple moving average is $35.65.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. Sell-side analysts predict that Mineralys Therapeutics will post -4.23 earnings per share for the current year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.